BioInvent International AB (CHIX:BINVS) Beta: N/A (As of Jul. 02, 2026)


CHIX:BINVS BioInvent International AB CHIX:BINVS
53 GF Score
Price kr34.75
GF Value kr71.54
! 4 Warning Signs
View Full Analysis

What is BioInvent International AB Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-02), BioInvent International AB's Beta is Not available.


BioInvent International AB  (CHIX:BINVs) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


BioInvent International AB Beta Related Terms


BioInvent International AB Beta Historical Data

* Premium members only.

The historical data trend for BioInvent International AB's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioInvent International AB Beta Chart

BioInvent International AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -0.40 -0.18 0.00

BioInvent International AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.16 -0.17 -0.19 0.00 0.00

CHIX:BINVS vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, BioInvent International AB's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioInvent International AB Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioInvent International AB's Beta distribution charts can be found below:

* The bar in red indicates where BioInvent International AB's Beta falls into.


CHIX:BINVS
53GF Score
BioInvent International AB CHIX:BINVS
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioInvent International AB Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Is BioInvent International AB (CHIX:BINVS) Overvalued in 2026?

Based on GuruFocus' analysis, BioInvent International AB stock appears to be undervalued. The current stock price of kr34.75 is trading 51.4% below its estimated GF Value™ of kr71.54.

Key valuation signals for CHIX:BINVS:

  • Beta: N/A
  • GF Value™: kr71.54 vs. price of kr34.75 (51.4% below fair value)
  • GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the CHIX:BINVS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioInvent International AB Business Description

Address Ideongatan 1, Lund, SWE, SE-223 70
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
53GF Score

Get the complete analysis for CHIX:BINVS

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr34.75
Price
kr71.54
GF Value